GoldenGolden
Mekonos

Mekonos

Mekonos is a company that creates cell-engineering platforms

Mekonos is a company that has created a platform that allows cell and gene therapies to be more accessible. The company was founded by Anil Narsimha, Greg Sitters, and Steven Banerjee in 2017, in San Francisco, California, United States.

Mekonos is responsible for developing over nine hundred therapeutic candidates, and expect roughly forty of them to be approved by the end of 2022. They developed their therapeutics through their platform solution, Iris, which is a System-on-a-Chip that allows for automated deliveries and precision for multiplexing.

Iris is a pharmaceutical and biotechnological platform that allows for targeted delivery and dose control of gene therapeutics that includes nucleic acids, protein complexes, and small molecules, and cell treatments such as primary, immune, and stem cells.

Microfluidics, micro-electro-mechanical systems, and chemistry to expand their catalogue of payloads and cell types. Their various methods of expansion allows Mekonos to scale their silicon technology for drug discover and development.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Mekonos Seed Funding Round June 2018
1,400,000
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Anil Narasimha

Founder

Antony van Hoorn

Investor

Darwin Ling

Investor

David Booth

Investor

Meng Ting Chung

Employee

Milad Alucozai

Investor

Seth Bindernagel

Investor

Steven Banerjee

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mekonos
November 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- Mekonos, a biotech company launching the first-of-its kind system-on-a-chip (SoC) for targeted ex vivo gene engineering, today announced it has...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.